Abbott Laboratories stock before the bell falls 2.6 percent

At the close on September 9, 2026, Abbott Laboratories stock ended at USD 105.52 on the NYSE after a 2.6 percent drop. The move followed FDA approval for the TactiFlex Duo catheter, while the S&P 500 finished lower on the same session.

Abbott Laboratories stock closed at USD 105.52 on the NYSE on September 9, 2026, after falling 2.6 percent. The stock also finished below the level cited earlier in the session, when it was 2.9 percent under the 52-week high.

September 9, 2026 recap

Abbott Laboratories Inc. (ISIN US0028241000, NYSE: ABT) lost ground after the FDA approved its TactiFlex Duo Ablation Catheter, as ad hoc news reported on September 10, 2026. The same report put the close at USD 105.52 and the daily move at minus 2.6 percent. It also said the shares were 2.9 percent below the 52-week high of USD 108.61.

For the broader market backdrop, the S&P 500 ended the session down 0.48 percent at 7,636.36, according to Kitco. Abbott did not move against that drift, and the stock traded in a narrow band around the close, with the same report citing 105.73 as the trading level mentioned alongside the session close.

Today before the open

The FDA approval of TactiFlex Duo remains the main fresh catalyst heading into today's session.